Sanofi gains after expanding Regeneron partnership with $8 billion deal

Sanofi's stock surged as much as 3.6% on Thursday, before settling at a 1.1% increase following the French pharmaceutical company's $8 billion agreement with Regeneron. This expansion of their partnership will see Sanofi pay Regeneron $1 billion upfront, with the potential for up to $7 billion in additional payments contingent upon meeting certain development, regulatory, and sales targets.

The deal involves the joint development and sale of four antibody-based medicines targeting immune system-related conditions. Regeneron will lead the development of these medicines, while Sanofi will be responsible for global sales. The first drug, REGN20423, is currently undergoing early-stage testing for atopic dermatitis, a common inflammatory skin condition.

The remaining three medicines are anticipated to commence human trials in 2027, with two still in the early stages of development. Additionally, Regeneron retains the option to incorporate Sanofi's experimental drug lunsekimig into the partnership after its late-stage testing for chronic obstructive pulmonary disease (COPD). The existing agreement governing the success of Dupixent, a product jointly developed by both companies and a major revenue source for Sanofi, remains unaffected.

The expanded partnership will enable Sanofi to gain access to new potential treatments, while simultaneously allowing Regeneron to retain its involvement in their development and commercialization.